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Will Cholesteryl Ester
Transfer Protein Inhibition
Succeed Primarily by
Lowering Low-Density
Lipoprotein Cholesterol?
Insights From Human
Genetics and Clinical Trials*
Sekar Kathiresan, MD
Boston and Cambridge, Massachusetts
Developing new medicines to treat atherosclerotic cardiovas-
cular disease (ASCVD), the leading cause of death in the
United States and in Europe, has never been more challenging
(1). The number of new drug approvals is down, whereas the
ost of developing a new medicine is increasing. Many new
rugs fail in the clinic because of efficacy, that is, the drug does
ot reduce risk for ASCVD when tested in humans.
See page 2041
To overcome these challenges, the pharmaceutical indus-
try is urgently searching for 2 solutions: “validated” gene
targets and biomarkers that predict cardiovascular outcomes
in a clinical trial (1,2). The term “validated” generally refers
to increased confidence that targeting the gene will reduce
risk of disease in humans. In addition to a validated gene
target, the drug development process requires a biomarker
that can help assess drug efficacy, dose-find in early clinical
development, and predict disease risk.
Over the last 3 decades, the biomedical research community
has intensively studied a specific gene target—CETP—and a
related biomarker—high-density lipoprotein (HDL)—for
their potential in altering risk for ASCVD (3,4). Studies in
cellular models, animal models, and humans have led to 2
hypotheses. The first, the cholesteryl ester transfer protein
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Dr. Kathiresan is a consultant to Merck, Pfizer, Celera, and Alnylam.(CETP) hypothesis, is focused on CETP as a gene target
and suggests that: 1) increased enzymatic activity of CETP
promotes atherosclerosis; and 2) inhibition of CETP activ-
ity will reduce risk for ASCVD (3). The second, the HDL
hypothesis, is focused on HDL as a biomarker and suggests
that: 1) lower levels of HDL (as measured by the cholesterol
content in HDL) increase risk for ASCVD; and 2) therapies
that raise HDL will lower risk for ASCVD (4). Despite
considerable research, the answers to both hypotheses re-
main unsettled, and in the last few years, several results have
challenged prior assumptions.
Against this background, in this issue of the Journal,
Johannsen et al. (5) use naturally occurring human genetic
variation to address these research questions. They test the
hypothesis that common genetic variation at the CETP
gene relates to plasma lipids and risk for incident ASCVD.
In 10,261 participants from the prospective Copenhagen
City Heart Study, they genotype 2 common single nucleo-
tide polymorphisms (CETP 629CA or rs1800775 and
Taq1BGA or rs708272) that have previously been asso-
ciated with decreased CETP mass and decreased CETP
activity (6,7). They find that the alleles associated with
lower CETP activity are associated with a range of lipid
biomarkers including: 1) higher apolipoprotein A-I con-
taining lipoproteins (as measured by HDL cholesterol);
2) lower apolipoprotein B–containing lipoproteins (as mea-
sured by low-density lipoprotein [LDL] cholesterol and
triglycerides); and 3) lower plasma lipoprotein(a) (Table 1).
They also test whether these polymorphisms associate with
traits relevant to the side effects of pharmacological CETP
inhibition and find no such associations.
Beyond enzymatic activity and biomarkers, genetics
has a unique potential to offer insights into human
disease endpoints (8). As such, the investigators’ primary
question was whether these CETP polymorphisms asso-
ciate with incident ASCVD and mortality. They find that
the CETP alleles associated with intermediate endpoints
lower CETP activity, higher HDL cholesterol, lower
DL cholesterol, lower triglycerides, and lower lipopro-
ein(a)) are indeed associated with decreased risk for
SCVD and mortality. Overall, these robust findings
onfirm the observations reported in a meta-analysis from
008 and 2 additional independent studies since then
Table 1) (7,9,10).
What are the implications of this study for the CETP
ypothesis and the HDL hypothesis? With regard to the
ETP hypothesis, these genetic association results seem
o “validate” CETP as a gene target and suggest that
rugs that inhibit CETP activity (and produce a similar
ipid profile as the gene variants) are likely to reduce risk
or ASCVD in clinical trials.
If so, how do we make sense of the failure of 2 different
ETP inhibitors—torcetrapib and dalcetrapib—to reduce
isk for ASCVD in large randomized controlled trials? For
orcetrapib, a leading possibility is off-target side effects. In
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ment to Understand Its Impact in Atherosclerotic Events)
randomized controlled trial involving 15,067 partici-
pants, torcetrapib increased HDL cholesterol by 72%,
decreased LDL cholesterol by 25%, and decreased trig-
lycerides by 9% (11). However, torcetrapib also increased
blood pressure and aldosterone level. On net, when
compared with placebo, torcetrapib treatment increased
risk for ASCVD by 25%.
If torcetrapib’s failure is potentially due to off-target
effects, how does one understand the recent failure of
dalcetrapib, a compound that did not have effects on
blood pressure or aldosterone levels (12)? The dal-
OUTCOMES trial randomized 15,000 participants to
test the hypothesis that CETP inhibition with dalce-
trapib will reduce cardiovascular morbidity and mortality
in patients with recent ACS. In May 2012, the data
safety and monitoring board stopped the trial at a second
interim analysis due to “lack of clinically meaningful
efficacy” (13). Dalcetrapib may have failed due to issues
related to clinical trial design such as insufficient statis-
tical power, insufficient duration of follow-up, and wrong
study population. As the study findings remain to be
published in a peer-reviewed journal, it is at present
difficult to evaluate these considerations.
Beyond study design, dalcetrapib’s failure may lie with
something more fundamental, the fact that dalcetrapib
raised HDL cholesterol in isolation. In contrast to other
CETP inhibitors, dalcetrapib only alters 1 lipid fraction–
HDL cholesterol (12). In Phase II clinical trials, dalce-
trapib raised HDL cholesterol by about 25% to 30%
without significant effects on LDL cholesterol, triglycer-
ides, or blood pressure (14). The dal-OUTCOMES
study investigators expected each 1 mg/dl increase in
HDL cholesterol to lead to a 1.5% relative risk reduction
in the primary ASCVD endpoint (14). The average
participant treated with dalcetrapib was expected to have
HDL cholesterol increase from 40 to 51 mg/dl, and this
increase was projected to correspond to a 15% reduction
in risk for the primary ASCVD endpoint. Critically,
these calculations rest on the validity of the HDL
hypothesis—that higher HDL causally protects from risk
for ASCVD.
However, several lines of human genetic evidence now
suggest that the epidemiologic association of higher
HDL cholesterol with lower risk for ASCVD may not
reflect a causal relationship. First, lifelong low HDL
cholesterol due to Mendelian mutations in 3 genes—
ABCA1, APOA1, or LCAT—is not consistently associated
with increased risk for ASCVD (reviewed in Vergeer et
al. [4]). Second, in the Copenhagen City Heart Study,
carriers of loss-of-function mutations in ABCA1 had 17
mg/dl lower HDL cholesterol but were not at increased
risk for ASCVD (15). Third, we recently reported that
2.6% of individuals carry an HDL cholesterol– boosting
variant in the endothelial lipase gene and despite havingGe T
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lower risk for myocardial infarction (10). Finally, we
evaluated 14 common variants that affected HDL cho-
lesterol in isolation (without affecting other lipid frac-
tions) and found that a genotype score crafted from these
variants did not relate to risk for myocardial infarction
(10). So, dalcetrapib may have failed because it altered
only a noncausal biomarker.
When combined, the dalcetrapib clinical trial results
and the human genetic findings summarized here cast
doubt on the notion that raising HDL cholesterol in
isolation will reduce risk for ASCVD. For several de-
cades, the biomedical research community has assumed
that if an intervention raises HDL cholesterol, then that
intervention will reduce risk for ASCVD. Now, it seems
prudent to rethink this assumption and re-evaluate the
use of HDL cholesterol as a biomarker predictive of
ASCVD in intervention studies.
In contrast with the HDL cholesterol biomarker,
human genetic studies strongly suggest that both LDL
cholesterol and plasma lipoprotein(a) cause ASCVD.
Rare mutations that lead to extremely high LDL choles-
terol consistently increase risk for ASCVD (16,17).
About 3% of individuals carry an LDL cholesterol–
lowering variant in the proprotein convertase subtilisin/
kexin type 9 gene, and these individuals are at lower risk
for myocardial infarction (18–20). A genotype score
crafted from 13 variants that affected LDL cholesterol in
isolation was strongly associated with myocardial infarc-
tion risk (10). In addition, polymorphisms that increase
plasma lipoprotein(a) consistently confer increased risk
for ASCVD (21–23).
What are the implications of these data for the 2
CETP inhibitors—anacetrapib and evacetrapib—that re-
main in clinical development (24,25)? These CETP
inhibitors do not seem to have off-target effects on blood
pressure or aldosterone. The pattern of lipid effects for
anacetrapib and evacetrapib (higher HDL cholesterol,
lower LDL cholesterol, lower triglycerides, and lower
lipoprotein(a)) mirrors that seen by Johannsen et al. for
the 2 CETP variants that are associated with lower
CETP activity and lower risk for ASCVD. As such, the
work of Johannsen et al. increases confidence that anac-
etrapib and evacetrapib will successfully reduce risk for
ASCVD.
By providing direct evidence in humans prior to a clinical
trial, studies of genetic variation such as that of Johannsen
et al. represent powerful approaches to validate gene targets
and pinpoint causal biomarkers. CETP inhibition by anac-
etrapib and evacetrapib is likely to succeed. However, we
have learned that any potential benefit clearly cannot be
ascribed to the HDL biomarker per se. Insights from
human genetics and the completed dalcetrapib trial suggest
that the success of CETP inhibitors may be more related to
their effect on LDL cholesterol and lipoprotein(a) rather
than through HDL elevation.Reprint requests and correspondence: Dr. Sekar Kathiresan,
Sekar Kathiresan, Massachusetts General Hospital, Center for
Human Genetic Research, 185 Cambridge Street, CPZN 5.252,
Boston, Massachusetts 02114. E-mail: skathiresan@partners.org.
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